Cytokine receptor-like factor 2 (CRLF2) encodes for a receptor protein that participates in activating STAT, possibly through JAK pathways. These pathways are important in immune system regulation. In cancer, CRLF2 rearrangements and one recurring mutation leading to CRLF2 overexpression have been identified in a subset of patients with high risk acute lymphoblastic leukemia who have an exceptionally dismal prognosis.

JAK and mTOR inhibitors have been explored in preclinical models as potential therapies targeting CRLF2-rearranged ALL (Maude et al. 2011; Tasian et al. 2012).

Related Pathways

Contributors: Valerie Brown, M.D., Ph.D., Scott C. Borinstein, M.D., Ph.D., Debra Friedman, M.D.

Suggested Citation: Brown, V., Borinstein, S.C., Friedman, D. 2015. CRLF2. My Cancer Genome (Updated December 2015)

Modified: December 7, 2015

Disclaimer: The information presented at is compiled from sources believed to be reliable. Extensive efforts have been made to make this information as accurate and as up-to-date as possible. However, the accuracy and completeness of this information cannot be guaranteed. Despite our best efforts, this information may contain typographical errors and omissions. The contents are to be used only as a guide, and health care providers should employ sound clinical judgment in interpreting this information for individual patient care.